ERBB2 and portal hypertension: noted higher incidences of noncirrhotic portal hypertension, splenomegaly, gastroesophageal varix formation, and spontaneous portosystemic shunting in patients treated with T-DM1 compared with those treated with the HER2-targeted tyrosine kinase inhibitor, lapatinib, in combination with capecitabine (a 5-Flourouracil prodrug) (17).